Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Brian Daikh (NPI 1184617953)

Field	Value
Entity Type	Individual
Organization	Brian Daikh
Address	51 Sewall St
City	Portland
State	ME
ZIP	04102
Taxonomy	Specialist
NPI Enumerated	August 26, 2005

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

This provider’s Medicare billing is dominated by infused biologic agents and infusion administration codes, consistent with a specialty practice focused on outpatient infusion therapy; the top three Medicare drugs are J9312 ($345.6K, 27.7%), J0129 ($312.8K, 25.1%), and J1602 ($269.8K, 21.6%), and infusion/biologic administration appears to be the core service line. The code-level mix (multiple large J‑codes for monoclonal antibodies and disease‑modifying biologics) indicates operational emphasis on in‑office drug administration rather than primary care or procedure‑heavy specialties.

Revenue is highly concentrated: the precomputed top-3 Medicare codes account for 74.5% of this provider’s total Medicare revenue, making a handful of drug administrations the critical drivers of the $1.2M in reported Medicare receipts. That concentration means changes to reimbursement or utilization of any one of these agents could materially affect overall revenue.

This provider is effectively single‑payer in the available data: $1.2M in total Medicare revenue is on file while there is no Medicaid billing on file, so Medicaid contributes $none to this profile and state Medicaid exposure is absent in the reported dataset. For analysts, that means payer mix risk is concentrated in Medicare and would require separate validation for commercial or Medicaid activity outside the dataset.

National competitive standing on the leading biologic drugs is moderate to solid but not dominant: J9312 ranks #58 of 317 providers nationally (82th percentile; typical, unremarkable volume for this code), J0129 ranks #533 of 1221 (56th percentile; typical, unremarkable volume for this code), and J1602 ranks #232 of 1041 (78th percentile; typical, unremarkable volume for this code). In short, the provider shows above‑median activity on some infusion agents but is not an extreme national outlier by the supplied rank/percentile descriptors.

Clinical visit and infusion procedure revenue is small relative to drug revenue: the primary E/M code 99214 generated $45.2K (3.6% of Medicare revenue) and 99213 generated $18K (1.4%), while chemotherapy administration 96413 generated $27.9K (2.2%) and initial infusion 96365 generated $12.7K (1.0%). These figures demonstrate that patient face‑to‑face visits and infusion administration fees are secondary revenue streams compared with the drug product payments themselves.

Ancillary diagnostics and basic clinic services are present but limited in scale: 36415 (phlebotomy) produced $5.3K and 36415 ranks #6162 of 86467 (93th percentile; typical, unremarkable volume for this code), 80053 (CMP) produced $4.4K, and imaging such as 77080 produced $1.1K. This pattern suggests some onsite lab and minor imaging support for infusion services but not a broad diagnostic or imaging center footprint.

The provider’s enrollment history shows long tenure: NPI enumerated 2005-08-26 (~21 years ago), indicating a stable, long‑standing Medicare billing presence that supports continuity in recorded patterns and makes trend analysis feasible over a multi‑year window if historical data are requested. This longevity reduces the chance that current billing patterns are from a very new or transient practice.

Although many codes are described as "typical, unremarkable volume for this code" in the supplied comparisons, the practice’s financial exposure is concentrated in a small set of high‑cost biologic drugs (e.g., J9312 avg paid/claim $64, J0129 avg paid/claim $34, J1602 avg paid/claim $11). From a payer or contracting perspective, that concentration creates sensitivity to formulary, supply, or reimbursement changes for those specific agents despite the absence of extreme rank outlier flags in the national comparison.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9312	Injection, rituximab, 10 mg	5,400	$60	$345.6K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,200	$30	$312.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	24,530	$10	$269.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,320	$30	$138.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	510	$90	$45.2K
J0897	Injection, denosumab, 1 mg	2,100	$20	$37.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	290	$100	$27.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	290	$60	$18K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	260	$50	$12.7K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	50	$110	$5.3K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

Brian Daikh — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9312	1	10	5,400	$60	$343.1K
J0129	1	10	6,880	$30	$207.2K
J1602	1	10	14,850	$10	$163.5K
J1745	2	10	5,320	$30	$121.4K
J0897	12	20	2,730	$20	$86.4K
96413	8	30	170	$100	$20.6K
99214	29	2,500	70	$70	$7.2K
90694	138	140	50	$80	$5.7K
96365	3	30	90	$50	$5.6K
99215	489	780	30	$100	$4.8K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Brian Daikh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainegeneral Medical Center	ME	General Acute Care Hospital	$0	$168.1M
Rachit Kumar	VA	Hematology & Oncology Physician	$802.4K	$0
Bo Pang	ME	Facial Plastic Surgery Physician	$434.3K	$0
Stephan Babirak	ME	Endocrinology, Diabetes & Metabolism Physician	$400K	$0
Kenneth Orourke	ME	Specialist	$381.7K	$0
Rheumatology Associates P.A.	ME	Specialist	$0	$381.2K
Mainegeneral Medical Center	ME	Family Medicine Physician	$0	$375.3K
Aamir Rai	TX	Anesthesiology Physician	$334.5K	$0
Brian Keroack	ME	Specialist	$326.6K	$0
David Rancourt	MA	Internal Medicine Physician	$315.4K	$0

Nearby Providers

Other providers in the same ZIP code as Brian Daikh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainehealth	ME	General Acute Care Hospital	$0	$142.6M
Shalom House, Inc.	ME	Mental Illness Community Based Residential Treatment Facility	$0	$81.9M
Mercy Hospital	ME	General Acute Care Hospital	$0	$35.5M
Maxim Healthcare Services, Inc.	ME	Home Health Agency	$0	$28.1M
Quality Care Access, LLC	ME	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$17.2M
Portland Community Health Center	ME	Federally Qualified Health Center (FQHC)	$0	$12.9M
Al-shawk Home Healthcare, LLC	ME	Personal Care Attendant	$0	$7M
Maine Eye Center, PA	ME	Ophthalmology Physician	$0	$6.1M
Hand Of Mercy Health Care, LLC	ME	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$6.1M
Mainehealth	ME	General Acute Care Hospital	$0	$5.5M

Brian Daikh — Billing Profile & Reimbursement Data

Sign up for Brian Daikh — Billing Profile & Reimbursement Data policy alerts

Brian Daikh — Billing Profile & Reimbursement Data

Sign up for Brian Daikh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References